aminolevulinic acid has been researched along with Liver Neoplasms in 37 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
Liver Neoplasms: Tumors or cancer of the LIVER.
Excerpt | Relevance | Reference |
---|---|---|
" Using 5-aminolevulinic acid (5-ALA), the pro-drug of PS protoporphyrin IX, we investigated the impact of PDT on hepatocellular carcinoma (HCC)." | 8.31 | An Efficient 5-Aminolevulinic Acid Photodynamic Therapy Treatment for Human Hepatocellular Carcinoma. ( Aoudjehane, L; Baydoun, M; Boleslawski, E; Conti, F; Delhem, N; Kumar, A; Leroux, B; Moralès, O; Pecquenard, F; Quilbé, A, 2023) |
" This research aimed to assess the cytogenetic potential of 5-aminolevulinic acid (5-ALA) activated with laser irradiation (5-ALA/PDT) to damage the intact DNA of adenocarcinoma breast cancer cell line (MCF-7) and hepatocellular carcinoma cell line (HepG2)." | 7.88 | Photodynamic therapy using 5-aminolevulinic acid triggered DNA damage of adenocarcinoma breast cancer and hepatocellular carcinoma cell lines. ( Abo-Elfadl, MT; Abo-Zeid, MAM; Mostafa, SM, 2018) |
" The aim of this study was to establish whether this might be applicable for hepatocellular carcinoma using protoporphyrin synthesized in the tissue from administered delta-aminolevulinic acid." | 7.69 | Photosensitization of experimental hepatocellular carcinoma with protoporphyrin synthesized from administered delta-aminolevulinic acid: studies with cultured cells and implanted tumors. ( Anderson, KE; Egger, NG; Gourley, WK; Motamedi, M; Schoenecker, JA; Weinman, SA, 1997) |
"We conclude from these in vitro and in vivo studies that porphyrin accumulation after administration of delta-aminolevulinic acid in this hepatoma is substantial and time dependent, and delivery of laser light locally can cause tumor photosensitization and necrosis." | 7.69 | Photosensitization of experimental hepatocellular carcinoma with protoporphyrin synthesized from administered delta-aminolevulinic acid: studies with cultured cells and implanted tumors. ( Anderson, KE; Egger, NG; Gourley, WK; Motamedi, M; Schoenecker, JA; Weinman, SA, 1997) |
"Backgtound/Aim: Since hepatocellular carcinoma (HCC) has a high recurrence rate, accurate diagnosis of its location and curative resection is important to improve survival." | 5.43 | Photodynamic Diagnosis of Hepatocellular Carcinoma Using 5-Aminolevulinic Acid. ( Fujiwara, H; Harada, K; Ichikawa, D; Ikoma, H; Kamada, Y; Morimura, R; Murayama, Y; Nishimura, M; Okamoto, K; Otsuji, E, 2016) |
"We used two human hepatoma cell lines (HuH-7 and Hep G2)." | 5.43 | Photodynamic Diagnosis of Hepatocellular Carcinoma Using 5-Aminolevulinic Acid. ( Fujiwara, H; Harada, K; Ichikawa, D; Ikoma, H; Kamada, Y; Morimura, R; Murayama, Y; Nishimura, M; Okamoto, K; Otsuji, E, 2016) |
"The acute hepatic porphyrias (AHP) are rare, inborn errors of heme-metabolism and include acute intermittent porphyria, hereditary coproporphyria, variegate porphyria, and porphyria due to severe deficiency of 5-aminolevulinic acid dehydratase." | 5.41 | AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. ( Balwani, M; Bonkovsky, HL; Lim, JK; Wang, B, 2023) |
" Using 5-aminolevulinic acid (5-ALA), the pro-drug of PS protoporphyrin IX, we investigated the impact of PDT on hepatocellular carcinoma (HCC)." | 4.31 | An Efficient 5-Aminolevulinic Acid Photodynamic Therapy Treatment for Human Hepatocellular Carcinoma. ( Aoudjehane, L; Baydoun, M; Boleslawski, E; Conti, F; Delhem, N; Kumar, A; Leroux, B; Moralès, O; Pecquenard, F; Quilbé, A, 2023) |
"Lenvatinib is an oral tyrosine kinase inhibitor (TKI), and has been applied in the clinical trials for the treatment of hepatocellular carcinoma (HCC)." | 4.31 | Low Dose of 5-Aminolevulinic Acid Hydrochloride Alleviates the Damage in Cardiomyocytes Induced by Lenvatinib via PI3K/AKT Signaling Pathway. ( Fu, H; Hu, C; Hu, F; Li, S; Lu, C; Shi, Y, 2023) |
"Porphyria was induced in vivo in mice using 3,5-diethoxycarbonyl-1,4-dihydrocollidine or in vitro by exposing human liver Huh7 cells and keratinocytes, or their lysates, to protoporphyrin-IX, other porphyrins, or to δ-aminolevulinic acid plus deferoxamine." | 3.91 | Oxygen and Conformation Dependent Protein Oxidation and Aggregation by Porphyrins in Hepatocytes and Light-Exposed Cells. ( Basrur, V; Carter, EL; Herrmann, H; Lehnert, N; Maitra, D; Nesvizhskii, AI; Omary, MB; Osawa, Y; Ragsdale, SW; Richardson, R; Rittié, L; Wolf, MW; Zhang, H, 2019) |
"Porphyrias are caused by porphyrin accumulation resulting from defects in the heme biosynthetic pathway that typically lead to photosensitivity and possible end-stage liver disease with an increased risk of hepatocellular carcinoma." | 3.91 | Oxygen and Conformation Dependent Protein Oxidation and Aggregation by Porphyrins in Hepatocytes and Light-Exposed Cells. ( Basrur, V; Carter, EL; Herrmann, H; Lehnert, N; Maitra, D; Nesvizhskii, AI; Omary, MB; Osawa, Y; Ragsdale, SW; Richardson, R; Rittié, L; Wolf, MW; Zhang, H, 2019) |
" This research aimed to assess the cytogenetic potential of 5-aminolevulinic acid (5-ALA) activated with laser irradiation (5-ALA/PDT) to damage the intact DNA of adenocarcinoma breast cancer cell line (MCF-7) and hepatocellular carcinoma cell line (HepG2)." | 3.88 | Photodynamic therapy using 5-aminolevulinic acid triggered DNA damage of adenocarcinoma breast cancer and hepatocellular carcinoma cell lines. ( Abo-Elfadl, MT; Abo-Zeid, MAM; Mostafa, SM, 2018) |
"Sorafenib is a multitargeted kinase inhibitor currently used in the treatment of advanced hepatocellular carcinoma (HCC)." | 3.85 | Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment. ( Borgia, F; Cannavò, SP; Franzè, MS; Lentini, M; Saitta, C; Vaccaro, M, 2017) |
"To examine the efficacy and mechanism of delta- or 5-aminolevulinic acid (ALA)-mediated photodynamic therapy (PDT) on a human hepatocellular carcinoma cell line." | 3.74 | Study of the efficacy and mechanism of ALA-mediated photodynamic therapy on human hepatocellular carcinoma cell. ( Ho, RJ; Huang, Z; Wong, CK; Yow, CM, 2007) |
" The aim of this study was to establish whether this might be applicable for hepatocellular carcinoma using protoporphyrin synthesized in the tissue from administered delta-aminolevulinic acid." | 3.69 | Photosensitization of experimental hepatocellular carcinoma with protoporphyrin synthesized from administered delta-aminolevulinic acid: studies with cultured cells and implanted tumors. ( Anderson, KE; Egger, NG; Gourley, WK; Motamedi, M; Schoenecker, JA; Weinman, SA, 1997) |
"We conclude from these in vitro and in vivo studies that porphyrin accumulation after administration of delta-aminolevulinic acid in this hepatoma is substantial and time dependent, and delivery of laser light locally can cause tumor photosensitization and necrosis." | 3.69 | Photosensitization of experimental hepatocellular carcinoma with protoporphyrin synthesized from administered delta-aminolevulinic acid: studies with cultured cells and implanted tumors. ( Anderson, KE; Egger, NG; Gourley, WK; Motamedi, M; Schoenecker, JA; Weinman, SA, 1997) |
"In 15 patients with hepatocellular carcinoma (HCC) and 14 patients with liver cirrhosis (LC), urinary excretions of delta-aminolevulinic acid (ALA), porphobilinogen (PBG), uroporphyrin (UP), coproporphyrin (CP), and erythrocyte contents of CP and protoporphyrin (PP) were examined." | 3.67 | Aberrant porphyrin metabolism in hepatocellular carcinoma. ( Hirayama, C; Horie, Y; Udagawa, M, 1984) |
"The exact mechanism of carcinogenesis of this rare tumor is unknown, however." | 3.01 | Heterogeneous molecular behavior in liver tumors (HCC and CCA) of two patients with acute intermittent porphyria. ( Beykirch, MK; Bronisch, O; Haverkamp, T; Knösel, T; Mogler, C; Petrides, PE; Rummeny, C; Schmid, C; Stauch, T; Weichert, W, 2023) |
"One patient had developed hepatocellular carcinoma (HCC), the other intrahepatic cholangiocarcinoma (CCA)." | 3.01 | Heterogeneous molecular behavior in liver tumors (HCC and CCA) of two patients with acute intermittent porphyria. ( Beykirch, MK; Bronisch, O; Haverkamp, T; Knösel, T; Mogler, C; Petrides, PE; Rummeny, C; Schmid, C; Stauch, T; Weichert, W, 2023) |
"Acute intermittent porphyria is the most common type of AHP, with an estimated prevalence of patients with symptoms of approximately 1 in 100,000." | 3.01 | AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. ( Balwani, M; Bonkovsky, HL; Lim, JK; Wang, B, 2023) |
"The acute hepatic porphyrias (AHP) are rare, inborn errors of heme-metabolism and include acute intermittent porphyria, hereditary coproporphyria, variegate porphyria, and porphyria due to severe deficiency of 5-aminolevulinic acid dehydratase." | 3.01 | AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. ( Balwani, M; Bonkovsky, HL; Lim, JK; Wang, B, 2023) |
"An increased incidence of hepatocellular carcinoma (HCC) has been reported as a long-term manifestation in symptomatic AIP patients." | 1.91 | Transcriptome profile analysis reveals putative molecular mechanisms of 5-aminolevulinic acid toxicity. ( Lichtenstein, F; Menezes, PR; Onuki, J; Pellegrina, DVDS; Reis, EM; Trufen, CEM, 2023) |
"Lenvatinib is an oral tyrosine kinase inhibitor (TKI), and has been applied in the clinical trials for the treatment of hepatocellular carcinoma (HCC)." | 1.91 | Low Dose of 5-Aminolevulinic Acid Hydrochloride Alleviates the Damage in Cardiomyocytes Induced by Lenvatinib via PI3K/AKT Signaling Pathway. ( Fu, H; Hu, C; Hu, F; Li, S; Lu, C; Shi, Y, 2023) |
"Porphyrias are caused by porphyrin accumulation resulting from defects in the heme biosynthetic pathway that typically lead to photosensitivity and possible end-stage liver disease with an increased risk of hepatocellular carcinoma." | 1.51 | Oxygen and Conformation Dependent Protein Oxidation and Aggregation by Porphyrins in Hepatocytes and Light-Exposed Cells. ( Basrur, V; Carter, EL; Herrmann, H; Lehnert, N; Maitra, D; Nesvizhskii, AI; Omary, MB; Osawa, Y; Ragsdale, SW; Richardson, R; Rittié, L; Wolf, MW; Zhang, H, 2019) |
"Porphyria was induced in vivo in mice using 3,5-diethoxycarbonyl-1,4-dihydrocollidine or in vitro by exposing human liver Huh7 cells and keratinocytes, or their lysates, to protoporphyrin-IX, other porphyrins, or to δ-aminolevulinic acid plus deferoxamine." | 1.51 | Oxygen and Conformation Dependent Protein Oxidation and Aggregation by Porphyrins in Hepatocytes and Light-Exposed Cells. ( Basrur, V; Carter, EL; Herrmann, H; Lehnert, N; Maitra, D; Nesvizhskii, AI; Omary, MB; Osawa, Y; Ragsdale, SW; Richardson, R; Rittié, L; Wolf, MW; Zhang, H, 2019) |
"Sorafenib is a multitargeted kinase inhibitor currently used in the treatment of advanced hepatocellular carcinoma (HCC)." | 1.46 | Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment. ( Borgia, F; Cannavò, SP; Franzè, MS; Lentini, M; Saitta, C; Vaccaro, M, 2017) |
"Backgtound/Aim: Since hepatocellular carcinoma (HCC) has a high recurrence rate, accurate diagnosis of its location and curative resection is important to improve survival." | 1.43 | Photodynamic Diagnosis of Hepatocellular Carcinoma Using 5-Aminolevulinic Acid. ( Fujiwara, H; Harada, K; Ichikawa, D; Ikoma, H; Kamada, Y; Morimura, R; Murayama, Y; Nishimura, M; Okamoto, K; Otsuji, E, 2016) |
"We used two human hepatoma cell lines (HuH-7 and Hep G2)." | 1.43 | Photodynamic Diagnosis of Hepatocellular Carcinoma Using 5-Aminolevulinic Acid. ( Fujiwara, H; Harada, K; Ichikawa, D; Ikoma, H; Kamada, Y; Morimura, R; Murayama, Y; Nishimura, M; Okamoto, K; Otsuji, E, 2016) |
"5-ALA fluorescence was detected in all hepatocellular carcinoma cases with serosa invasion." | 1.40 | Fluorescence detection of malignant liver tumors using 5-aminolevulinic acid-mediated photodynamic diagnosis: principles, technique, and clinical experience. ( Hayashi, M; Hirokawa, F; Inoue, Y; Komeda, K; Tanaka, R; Uchiyama, K, 2014) |
"In liver metastasis from colorectal cancer cases with serosa invasion, 18 patients (85." | 1.40 | Fluorescence detection of malignant liver tumors using 5-aminolevulinic acid-mediated photodynamic diagnosis: principles, technique, and clinical experience. ( Hayashi, M; Hirokawa, F; Inoue, Y; Komeda, K; Tanaka, R; Uchiyama, K, 2014) |
"Precise staging of gastric cancer is essential when selecting for the appropriate treatment approach." | 1.38 | Staging fluorescence laparoscopy for gastric cancer by using 5-aminolevulinic acid. ( Fujiwara, H; Harada, Y; Ichikawa, D; Ikoma, H; Koizumi, N; Kokuba, Y; Komatsu, S; Kubota, T; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Takamatsu, T, 2012) |
"ALA/protoporphyrin IX (PpIX) was mainly located in the cytoplasm of HepG2 cells." | 1.34 | Study of the efficacy and mechanism of ALA-mediated photodynamic therapy on human hepatocellular carcinoma cell. ( Ho, RJ; Huang, Z; Wong, CK; Yow, CM, 2007) |
"5-Aminolevulinic acid (ALA) is a precursor to heme synthesis pathway and currently used to induce endogenous protoporphyrin IX (PpIX, a potent photosensitizer) for photodynamic therapy of cancer." | 1.31 | Comparison of 5-aminolevulinic acid and its hexylester mediated photodynamic action on human hepatoma cells. ( Chen, JY; Peng, Q; Ren, QG; Wu, SM, 2002) |
"Hepatocellular carcinoma was confirmed by the histological examination of several biopsies drawn from suspicious areas." | 1.31 | Feasibility and diagnostic impact of fluorescence-based diagnostic laparoscopy in hepatocellular carcinoma: a case report. ( Arnold, JC; Riemann, JF; Schneider, AR; Zöpf, T, 2002) |
"The main tumor and the satellite metastases clearly showed intense fluorescence compared with unaffected liver parenchyma and other abdominal organs." | 1.31 | Feasibility and diagnostic impact of fluorescence-based diagnostic laparoscopy in hepatocellular carcinoma: a case report. ( Arnold, JC; Riemann, JF; Schneider, AR; Zöpf, T, 2002) |
"5-Aminolevulinic acid (ALA) is a heme precursor that accumulates in acute intermittent porphyria (AIP) due to enzymatic deficiencies in the heme biosynthetic pathway Its accumulation has been associated with several symptoms, such as abdominal pain attacks, neuromuscular weaknesses, neuropsychiatric alterations and increased hepatocellular carcinoma (HCC) incidence." | 1.31 | Is 5-aminolevulinic acid involved in the hepatocellular carcinogenesis of acute intermittent porphyria? ( Cadet, J; Di Mascio, P; Dörnemann, D; Douki, T; Medeiros, MH; Onuki, J; Teixeira, PC, 2002) |
"In 15 patients with hepatocellular carcinoma (HCC) and 14 patients with liver cirrhosis (LC), urinary excretions of delta-aminolevulinic acid (ALA), porphobilinogen (PBG), uroporphyrin (UP), coproporphyrin (CP), and erythrocyte contents of CP and protoporphyrin (PP) were examined." | 1.27 | Aberrant porphyrin metabolism in hepatocellular carcinoma. ( Hirayama, C; Horie, Y; Udagawa, M, 1984) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (5.41) | 18.7374 |
1990's | 5 (13.51) | 18.2507 |
2000's | 10 (27.03) | 29.6817 |
2010's | 13 (35.14) | 24.3611 |
2020's | 7 (18.92) | 2.80 |
Authors | Studies |
---|---|
Haverkamp, T | 1 |
Bronisch, O | 1 |
Knösel, T | 1 |
Mogler, C | 1 |
Weichert, W | 1 |
Stauch, T | 1 |
Schmid, C | 1 |
Rummeny, C | 1 |
Beykirch, MK | 1 |
Petrides, PE | 1 |
Wang, B | 1 |
Bonkovsky, HL | 1 |
Lim, JK | 1 |
Balwani, M | 1 |
Menezes, PR | 2 |
Trufen, CEM | 1 |
Lichtenstein, F | 1 |
Pellegrina, DVDS | 1 |
Reis, EM | 1 |
Onuki, J | 4 |
Kumar, A | 1 |
Pecquenard, F | 1 |
Baydoun, M | 1 |
Quilbé, A | 1 |
Moralès, O | 1 |
Leroux, B | 1 |
Aoudjehane, L | 1 |
Conti, F | 1 |
Boleslawski, E | 1 |
Delhem, N | 1 |
Shi, Y | 1 |
Hu, F | 1 |
Fu, H | 1 |
Li, S | 1 |
Lu, C | 1 |
Hu, C | 1 |
Lissing, M | 1 |
Wester, A | 1 |
Vassiliou, D | 1 |
Floderus, Y | 1 |
Harper, P | 1 |
Sardh, E | 1 |
Wahlin, S | 1 |
Ozten, O | 1 |
Guney Eskiler, G | 1 |
Sonmez, F | 1 |
Yıldız, MZ | 1 |
Borgia, F | 1 |
Saitta, C | 1 |
Vaccaro, M | 1 |
Franzè, MS | 1 |
Lentini, M | 1 |
Cannavò, SP | 1 |
Abo-Zeid, MAM | 1 |
Abo-Elfadl, MT | 1 |
Mostafa, SM | 1 |
Nakano, T | 1 |
Moriya, K | 1 |
Koike, K | 1 |
Horie, T | 1 |
González, CB | 1 |
DeSouza, AO | 1 |
Maria, DA | 1 |
Maitra, D | 1 |
Carter, EL | 1 |
Richardson, R | 1 |
Rittié, L | 1 |
Basrur, V | 1 |
Zhang, H | 1 |
Nesvizhskii, AI | 1 |
Osawa, Y | 1 |
Wolf, MW | 1 |
Ragsdale, SW | 1 |
Lehnert, N | 1 |
Herrmann, H | 1 |
Omary, MB | 1 |
Inoue, Y | 2 |
Tanaka, R | 1 |
Komeda, K | 1 |
Hirokawa, F | 2 |
Hayashi, M | 2 |
Uchiyama, K | 2 |
Laafi, J | 1 |
Homedan, C | 1 |
Jacques, C | 1 |
Gueguen, N | 1 |
Schmitt, C | 1 |
Puy, H | 1 |
Reynier, P | 1 |
Carmen Martinez, M | 1 |
Malthièry, Y | 1 |
Kaibori, M | 1 |
Matsui, K | 1 |
Ishizaki, M | 1 |
Iida, H | 1 |
Okumura, T | 1 |
Sakaguchi, T | 1 |
Inoue, K | 1 |
Ikeura, T | 1 |
Asano, H | 1 |
Kon, M | 1 |
Nishimura, M | 1 |
Murayama, Y | 2 |
Harada, K | 1 |
Kamada, Y | 1 |
Morimura, R | 1 |
Ikoma, H | 2 |
Ichikawa, D | 2 |
Fujiwara, H | 2 |
Okamoto, K | 2 |
Otsuji, E | 2 |
Imai, Y | 1 |
Fujii, K | 1 |
Kishi, K | 1 |
Fujiwara, Y | 1 |
Yano, M | 1 |
Inoue, M | 1 |
Miyashiro, I | 1 |
Motoori, M | 1 |
Shingai, T | 1 |
Gotoh, K | 1 |
Takahashi, H | 1 |
Noura, S | 1 |
Yamada, T | 1 |
Ohue, M | 1 |
Ohigashi, H | 1 |
Ishikawa, O | 1 |
Koizumi, N | 1 |
Komatsu, S | 1 |
Shiozaki, A | 1 |
Kuriu, Y | 1 |
Kubota, T | 1 |
Nakanishi, M | 1 |
Harada, Y | 1 |
Ochiai, T | 1 |
Kokuba, Y | 1 |
Takamatsu, T | 1 |
Ren, QG | 1 |
Wu, SM | 1 |
Peng, Q | 1 |
Chen, JY | 1 |
Schneider, AR | 2 |
Zöpf, T | 2 |
Arnold, JC | 2 |
Riemann, JF | 2 |
Weickert, U | 1 |
Till, H | 1 |
Bergmann, F | 1 |
Metzger, R | 1 |
Haeberle, B | 1 |
von Schweinitz, D | 1 |
Prosst, R | 1 |
Yow, CM | 1 |
Wong, CK | 1 |
Huang, Z | 1 |
Ho, RJ | 1 |
Alvarez, MG | 1 |
Lacelli, MS | 1 |
Rivarola, V | 1 |
Batlle, A | 1 |
Fukuda, H | 1 |
Takeda, O | 1 |
Takechi, S | 1 |
Ito, S | 1 |
Omori, H | 1 |
Katoh, T | 1 |
Yamaguchi, T | 1 |
Morofuji, Y | 1 |
Matsuo, T | 1 |
Toyoda, K | 1 |
Takeshita, T | 1 |
Hirose, M | 1 |
Hirao, T | 1 |
Hayashi, Y | 1 |
Tsutsumi, K | 1 |
Abe, K | 1 |
Nagata, I | 1 |
Udagawa, M | 1 |
Horie, Y | 1 |
Hirayama, C | 1 |
Egger, NG | 1 |
Schoenecker, JA | 1 |
Gourley, WK | 1 |
Motamedi, M | 1 |
Anderson, KE | 1 |
Weinman, SA | 1 |
Liu, DL | 1 |
Svanberg, K | 1 |
Wang, I | 1 |
Andersson-Engels, S | 1 |
Svanberg, S | 1 |
Douki, T | 2 |
Medeiros, MH | 2 |
Bechara, EJ | 1 |
Cadet, J | 2 |
Di Mascio, P | 2 |
De Siervi, A | 1 |
Vazquez, ES | 1 |
Rezaval, C | 1 |
Rossetti, MV | 1 |
del Batlle, AM | 1 |
Teixeira, PC | 1 |
Dörnemann, D | 1 |
Fisch, RO | 1 |
McCabe, ER | 1 |
Doeden, D | 1 |
Koep, LJ | 1 |
Kohlhoff, JG | 1 |
Silverman, A | 1 |
Starzl, TE | 1 |
Wainstok de Calmanovici, R | 1 |
Cochón, AC | 1 |
Zenklusen, JC | 1 |
Aldonatti, C | 1 |
Cabral, JR | 1 |
San Martín de Viale, LC | 1 |
Visser, O | 1 |
van den Berg, JW | 1 |
Koole-Lesuis, H | 1 |
Voortman, G | 1 |
Wilson, JH | 1 |
Xie, R | 1 |
Xu, T | 1 |
Zhu, J | 1 |
Wei, X | 1 |
Zhu, W | 1 |
Li, L | 1 |
Wang, Y | 1 |
Han, Y | 1 |
Zhou, J | 1 |
Bai, Y | 1 |
2 reviews available for aminolevulinic acid and Liver Neoplasms
Article | Year |
---|---|
Heterogeneous molecular behavior in liver tumors (HCC and CCA) of two patients with acute intermittent porphyria.
Topics: Adult; Aminolevulinic Acid; Carcinogenesis; Carcinoma, Hepatocellular; Female; Flavoproteins; Humans | 2023 |
AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.
Topics: Abdominal Pain; Aminolevulinic Acid; Antiemetics; Carcinoma, Hepatocellular; Creatinine; Female; Hem | 2023 |
35 other studies available for aminolevulinic acid and Liver Neoplasms
Article | Year |
---|---|
Transcriptome profile analysis reveals putative molecular mechanisms of 5-aminolevulinic acid toxicity.
Topics: Aminolevulinic Acid; Carcinogenesis; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Porphyria, | 2023 |
An Efficient 5-Aminolevulinic Acid Photodynamic Therapy Treatment for Human Hepatocellular Carcinoma.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Culture Media, Conditione | 2023 |
Low Dose of 5-Aminolevulinic Acid Hydrochloride Alleviates the Damage in Cardiomyocytes Induced by Lenvatinib via PI3K/AKT Signaling Pathway.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Hepatocellular; Liver Neoplasms; Mammals; Mice; Myocytes, C | 2023 |
Porphyrin precursors and risk of primary liver cancer in acute intermittent porphyria: A case-control study of 188 patients.
Topics: Aged; Aminolevulinic Acid; Case-Control Studies; Humans; Liver Neoplasms; Middle Aged; Porphobilinog | 2023 |
Investigation of the therapeutic effect of 5-aminolevulinic acid based photodynamic therapy on hepatocellular carcinoma.
Topics: Aminolevulinic Acid; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Photochem | 2022 |
Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Humans; Liver | 2017 |
Photodynamic therapy using 5-aminolevulinic acid triggered DNA damage of adenocarcinoma breast cancer and hepatocellular carcinoma cell lines.
Topics: Adenocarcinoma; Aminolevulinic Acid; Breast Neoplasms; Carcinoma, Hepatocellular; DNA Damage; Hep G2 | 2018 |
Hepatitis C virus core protein triggers abnormal porphyrin metabolism in human hepatocellular carcinoma cells.
Topics: Aminolevulinic Acid; Biosynthetic Pathways; Carcinoma, Hepatocellular; Cells, Cultured; Hep G2 Cells | 2018 |
Effect of 5-aminolevulinic acid on the expression of carcinogenesis-related proteins in cultured primary hepatocytes.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cell Proliferati | 2018 |
Oxygen and Conformation Dependent Protein Oxidation and Aggregation by Porphyrins in Hepatocytes and Light-Exposed Cells.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Hepatocellular; Cell Line; Deferoxamine; Heme; Hepatocytes; | 2019 |
Fluorescence detection of malignant liver tumors using 5-aminolevulinic acid-mediated photodynamic diagnosis: principles, technique, and clinical experience.
Topics: Aged; Aminolevulinic Acid; Anastomotic Leak; Carcinoma, Hepatocellular; Color; Colorectal Neoplasms; | 2014 |
Pro-oxidant effect of ALA is implicated in mitochondrial dysfunction of HepG2 cells.
Topics: Adenosine Triphosphate; Aminolevulinic Acid; Antioxidants; Blotting, Western; Carcinoma, Hepatocellu | 2014 |
Intraoperative Detection of Superficial Liver Tumors by Fluorescence Imaging Using Indocyanine Green and 5-aminolevulinic Acid.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Diagnostic Imaging; Female; Fluorescence; Fluorescent | 2016 |
Photodynamic Diagnosis of Hepatocellular Carcinoma Using 5-Aminolevulinic Acid.
Topics: Aged; Aminolevulinic Acid; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Embolization, Thera | 2016 |
The utility of 5-aminolevulinic acid-mediated photodynamic diagnosis in the detection of intraoperative bile leakage.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Anastomotic Leak; Bile; Child; Chil | 2017 |
Staging laparoscopy using ALA-mediated photodynamic diagnosis improves the detection of peritoneal metastases in advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Animals; Disease Models, Animal; Female; Fluorescence; | 2012 |
Staging fluorescence laparoscopy for gastric cancer by using 5-aminolevulinic acid.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aminolevulinic Acid; Female; Fluorescence; Humans; La | 2012 |
Comparison of 5-aminolevulinic acid and its hexylester mediated photodynamic action on human hepatoma cells.
Topics: Aminolevulinic Acid; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Photochemotherapy; Photosen | 2002 |
Feasibility and diagnostic impact of fluorescence-based diagnostic laparoscopy in hepatocellular carcinoma: a case report.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Hepatocellular; Female; Fluorescence; Humans; Laparoscopy; Lig | 2002 |
Improved preoperative tumor staging by 5-aminolevulinic acid induced fluorescence laparoscopy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Digestive System Neoplasm | 2005 |
Laparoscopic fluorescence diagnosis of peritoneal metastases from human hepatoblastoma in nude rats.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Disease Models, Animal; Fluorescence; Fluorescent Dy | 2006 |
Study of the efficacy and mechanism of ALA-mediated photodynamic therapy on human hepatocellular carcinoma cell.
Topics: Aminolevulinic Acid; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug The | 2007 |
5-aminolevulinic acid-mediated photodynamic therapy on Hep-2 and MCF-7c3 cells.
Topics: Adenocarcinoma; Aminolevulinic Acid; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; D | 2007 |
Effects of phenyl derivatives of dihydropyrazines with ability to generate radical species on Escherichia coli.
Topics: Aminolevulinic Acid; Copper; DNA; DNA Repair; Electron Spin Resonance Spectroscopy; Escherichia coli | 2007 |
[Skull metastasis of hepatocellular carcinoma successfully treated by intraoperative photodynamic diagnosis using 5-aminolevulinic acid: case report].
Topics: Aminolevulinic Acid; Carcinoma, Hepatocellular; Fluorescence; Humans; Intraoperative Period; Liver N | 2007 |
Aberrant porphyrin metabolism in hepatocellular carcinoma.
Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Hepatocellular; Erythrocytes; Female; Humans; Injection | 1984 |
Photosensitization of experimental hepatocellular carcinoma with protoporphyrin synthesized from administered delta-aminolevulinic acid: studies with cultured cells and implanted tumors.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Hepatocellular; In Vitro Techniques; Laser Therapy; Liver; | 1997 |
Laser Doppler perfusion imaging: new technique for determination of perfusion and reperfusion of splanchnic organs and tumor tissue.
Topics: Aminolevulinic Acid; Animals; Azepines; Intestines; Ischemia; Laser-Doppler Flowmetry; Liver; Liver | 1997 |
DNA alkylation by 4,5-dioxovaleric acid, the final oxidation product of 5-aminolevulinic acid.
Topics: Alkylation; Aminolevulinic Acid; DNA Adducts; DNA Damage; Guanine; Humans; Liver Neoplasms; Mutagene | 1998 |
Delta-aminolevulinic acid cytotoxic effects on human hepatocarcinoma cell lines.
Topics: Aminolevulinic Acid; Carcinoma, Hepatocellular; Cell Cycle; DNA Fragmentation; DNA, Neoplasm; Dose-R | 2002 |
Is 5-aminolevulinic acid involved in the hepatocellular carcinogenesis of acute intermittent porphyria?
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aminolevulinic Acid; Animals; Deoxyguanosine; DNA; DNA Damage; Liver Ne | 2002 |
Homotransplantation of the liver in a patient with hepatoma and hereditary tyrosinemia.
Topics: Aminolevulinic Acid; Carcinoma, Hepatocellular; Child; Female; Fructose-Bisphosphate Aldolase; Human | 1978 |
Influence of hepatic tumors caused by diethylnitrosamine on hexachlorobenzene-induced porphyria in rats.
Topics: 5-Aminolevulinate Synthetase; Aminolevulinic Acid; Animals; Carcinoma, Hepatocellular; Cytochrome P- | 1991 |
Porphyrin synthesis by human hepatocytes and HepG2 cells--effects of enzyme inducers and delta-aminolevulinic acid.
Topics: Aminolevulinic Acid; Carcinoma, Hepatocellular; Cells, Cultured; Cytochrome P-450 Enzyme System; Dim | 1991 |
The Combination of Glycolytic Inhibitor 2-Deoxyglucose and Microbubbles Increases the Effect of 5-Aminolevulinic Acid-Sonodynamic Therapy in Liver Cancer Cells.
Topics: Aminolevulinic Acid; Antimetabolites; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; De | 2017 |